• Shivani sharma
• Mohini kapoor
• Ramica sharma

Finerenone is a novel, selective, nonsteroidal MRA that is efficacious in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). Steroidal MR antagonists (MRAS) are included in treatment paradigms for resistant hypertension and heart failure with reduced ejection fraction, while the nonsteroidal MRA finerenone was shown to reduce renal and cardiovascular outcomes in two large phase III trials (FIDELIO-DKD and FIGARO-DKD) in patients with chronic kidney disease and type 2 diabetes, respectively.

FIDELIO-DKD (Finerenone),Mineralocorticoid receptor (MRAs), chronic kidney disease (CKD), sodium-glucose cotransporter-2 inhibitor (SGLT-2i), renin-angiotensin system (RAS).

"RECENT UPDATES ON FENERENONE", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.10, Issue 10, page no.e346-e354, October-2023, Available :http://www.jetir.org/papers/JETIR2310358.pdf

"RECENT UPDATES ON FENERENONE", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.10, Issue 10, page no. ppe346-e354, October-2023, Available at : http://www.jetir.org/papers/JETIR2310358.pdf